Talaris Therapeutics, Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $2.78 |
| Prev. Close | $2.74 |
| EPS | -1.74 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 14, 2023 |
| Dividend Yield % | - |
| Market Cap | $116.44M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 2.69 | 2.79 |
| 52 Week Range | 0.89 | 3.29 |
| Ratios | |
|---|---|
| P/B Ratio | 0.28 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$62.77M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -41.64% |
| EPS | -1.74 |
Score Breakdown
All Score (53 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| TALS | Market | |
|---|---|---|
| Value | 52 | 42 |
| Quality | 39 | 46 |
| Ownership | 36 | 39 |
| Growth | 60 | 44 |
| Dividends | - | 32 |
All Score (53 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Talaris Therapeutics, Inc. (TALS)
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Mary Kay Fenton
- Headquarters
- Wellesley
- Employees
- 84
Keep an eye on Talaris Therapeutics, Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.